Erratum: Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: The HARMONIZE randomized clinical trial (JAMA (2014) 312:21 (2223-2233) DOI: 10.1001/jama.2014.15688);Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: The HARMONIZE randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 312, Issue 21, 2014, Pages 2223-2233

  Kosiborod, Mikhail ^a,b   Rasmussen, Henrik S ^c   Lavin, Philip ^d   Qunibi, Wajeh Y ^e   Spinowitz, Bruce ^f   Packham, David ^g   Roger, Simon D ^h   Yang, Alex ⁱ   Lerma, Edgar ^j,k   Singh, Bhupinder ^c  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c ZS Pharma   (United States)

^d Boston Biostatistics Research Foundation   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h Renal Research   (Australia)

ⁱ Xelay Acumen Inc   (United States)

^j UNIVERSITY OF ILLINOIS   (United States)

^k ADVOCATE CHRIST MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; POTASSIUM; SODIUM; SODIUM ZIRCONIUM CYCLOSILICATE; SILICATE; ZIRCONIUM;

ADULT; ADVERSE OUTCOME; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PHASE 3 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SODIUM URINE LEVEL; SOUTH AFRICA; UNITED STATES; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED; OUTPATIENT;

ADULT; DOUBLE-BLIND METHOD; EDEMA; FEMALE; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; OUTPATIENTS; POTASSIUM; SILICATES; ZIRCONIUM;

EID: 84914703676     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.17494     Document Type: Erratum

References (38)

1. Khanagavi J, Gupta T, Aronow WS, et al. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch Med Sci. 2014;10(2):251-257.
2. An JN, Lee JP, Jeon HJ, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care. 2012;16(6):R225.
3. Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109(10):1510-1513.
4. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(3):542-551.
5. Ahn SY, Ryu J, Baek SH, et al. Incident chronic kidney disease and newly developed complications related to renal dysfunction in an elderly population during 5 years: a community-based elderly population cohort study. PLoS One. 2013;8(12):e84467.
6. Palmer BF, Fenves AZ. Optimizing blood pressure control in patients with chronic kidney disease. Proc (Bayl Univ Med Cent). 2010;23(3):239-245.
7. Vardeny O, Claggett B, Anand I, et al; Randomized Aldactone Evaluation Study (RALES) Investigators. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014;7(4):573-579.
8. St Peter WL, Odum LE, Whaley-Connell AT. To RAS or not to RAS? the evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. Pharmacotherapy. 2013;33(5):496-514.
9. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-551.
10. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010;21(5):733-735.
11. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126(3):264.e9-264.e24.
12. Yuan CM, Nee R, Little DJ, Abbott KC. Incidence of sodium polystyrene sulfonate-associated colonic necrosis. Am J Med. 2013;126(9):e13.
13. Aaron KJ, Sanders PW. Role of dietary salt and potassium intake in cardiovascular health and disease: a review of the evidence. Mayo Clin Proc. 2013;88(9):987-995.
14. Ash S, Singh B, Lavin P, Stavros F, Rasmussen H. Safety and efficacy of ZS-9, a novel selective cation trap, for treatment of hyperkalemia in CKD patients [abstract]. J Am Soc Nephrol. 2013;24:2B.
15. El Shahawy M, Rasmussen H, Lavin P, Yang A, Packham D. Acute-phase efficacy in a phase 3 multicenter, randomised, double-blind, placebo-controlled trial of ZS-9 for hyperkalaemia. Poster presented at 51st European Renal Association and European Dialysis and Transplant Association Congress 2014. http://www.postersessiononline.eu/pr/aula-poster.asp?congreso=796093165. Accessed October 24, 2014.
16. Weinberg JM, Appel LJ, Bakris G, et al; African American Study of Hypertension and Kidney Disease Collaborative Research Group. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009;169(17):1587-1594.
17. Rossignol P, Dobre D, McMurray JJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014;7(1):51-58.
18. Vardeny O, Cavallari LH, Claggett B, et al; Randomized Aldactone Evaluation Study (RALES) Investigators. Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail. 2013;6(5):970-976.
19. Burton P, Gurrin L, Sly P. Extending the simple linear regression model to account for correlated responses: an introduction to generalized estimating equations and multi-levelmixed modelling. Stat Med. 1998;17(11):1261-1291.
20. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156-1162.
21. McMahon GM, Mendu ML, Gibbons FK, Christopher KB. Association between hyperkalemia at critical care initiation and mortality. Intensive Care Med. 2012;38(11):1834-1842.
22. Goyal A, Spertus JA, Gosch K, et al. Serum potassium levels and mortality in acutemyocardial infarction. JAMA. 2012;307(2):157-164.
23. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10(4):297-303.
24. Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients. Am J Med Sci. 2014;347(2):93-100.
25. Łoniewski I, Wesson DE. Bicarbonate therapy for prevention of chronic kidney disease progression. Kidney Int. 2014;85(3):529-535.
26. Blumberg A, Weidmann P, Ferrari P. Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. Kidney Int. 1992;41(2):369-374.
27. Abramowitz MK, Melamed ML, Bauer C, Raff AC, Hostetter TH. Effects of oral sodium bicarbonate in patients with CKD. Clin J Am Soc Nephrol. 2013;8(5):714-720.
28. Goraya N, Wesson DE. Dietary management of chronic kidney disease: protein restriction and beyond. Curr Opin Nephrol Hypertens. 2012;21(6):635-640.
29. Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia. Int J Clin Pharm. 2013;35(6):1099-1104.
30. Cohn JN. Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. Adv Ther. 2007;24(6):1290-1304.
31. Kessler C, Ng J, Valdez K, Xie H, Geiger B. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J Hosp Med. 2011;6(3):136-140.
32. Scherr L, Ogden DA, Mead AW, Spritz N, Rubin AL. Management of hyperkalemia with a cation-exchange resin. N Engl J Med. 1961;264:115-119.
33. Flinn RB, Merrill JP, Welzant WR. Treatment of the oliguric patient with a new sodium-exchange resin and sorbitol; a preliminary report. N Engl J Med. 1961;264:111-115.
34. Watson M, Abbott KC, Yuan CM. Damned if you do, damned if you don't: potassium binding resins in hyperkalemia. Clin J Am Soc Nephrol. 2010;5(10): 1723-1726.
35. Watson MA, Baker TP, Nguyen A, et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. Am J Kidney Dis. 2012;60(3):409-416.
36. Tongyoo A, Sriussadaporn E, Limpavitayaporn P, Mingmalairak C. Acute intestinal obstruction due to Kalimate, a potassium-lowering agent: a case report and literature review. J Med Assoc Thai. 2013;96(12):1617-1620.
37. Castillo-Cejas MD, De-Torres-Ramírez I, Alonso-Cotoner C. Colonic necrosis due to calcium polystyrene sulfonate (Kalimate) not suspended in sorbitol. Rev Esp Enferm Dig. 2013;105(4):232-234.
38. Yang A, Leon A, Nuttall M, Low J, Rasmussen H. In vitro ion exchange capacity and selectivity of ZS-9, a novel, selective cation trap for the treatment of hyperkalemia. Am J Kidney Dis. 2014; 63(5):B115.